Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Intellia and Kyverna announced an exclusive agreement to develop and later commercialize an allogeneic CD19 CAR T-cell therapy to treat a wide range of B cell-mediated autoimmune illnesses.
A billion-dollar real estate project is coming to Morrisville, NC, as developers hope to capitalize on the growing biotechnology industry in the state’s Research Triangle.
Biopharma and life sciences companies and organizations provide updates on their businesses and pipelines.
It’s been a busy day for collaboration announcements in the life sciences world. Here are some of the top stories for today.
Several biopharma companies have adjusted their leadership teams to include new chief executive officers who are expected to guide the companies and their programs into the future.
Overall, the decision to hold the conferences virtually again this year is being met with what appears to be a bit of relief.
A bispecific antibody discovered by Twist Bioscience and licensed to Revelar Biotherapeutics neutralizes both the Omicron and Delta variants of SARS-CoV-2 in studies with the live virus.
With the beginning of a new year, many biopharmaceutical companies are reporting financial raises to advance their pipelines. BioSpace takes a quick look at some of them.
Pfizer and BioNTech are developing a vaccine for the prevention of shingles while Moderna is in a Phase I study of an mRNA vaccine for the Epstein-Barr Virus.
Mark Charest, Ph.D., of LifeSci Fund Management, said the J.P. Morgan Healthcare Conference will set the tone for biotech stock performance in 1H 2022.
Evidence continues to accumulate suggesting that Omicron, although significantly more infectious than previous COVID-19 strains, causes less severe disease.
Here’s who rang in the New Year by joining the NASDAQ or raising private equity funds.